Psychiatrische Indikationen für Benzodiazepine

  • G. Laakmann
  • D. Blaschke
Conference paper

Zusammenfassung

Benzodiazepine werden von ihrem Wirkungsspektrum her zur Gruppe der Tranquilizer gerechnet. Geht man der klassischen Aufteilung der Psychopharmaka nach, so bilden die Tranquilizer neben den Neuroleptika und den Antidepressiva die dritte große Gruppe der Psychopharmaka.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Ackenheil M (1985). Arzneimitteltherapie heute Band 36. Spektrum PsychopharmakaGoogle Scholar
  2. 2.
    AMDP (1979). Arbeitsgemeinschaft für Methodik und Dokumentation in der Psychiatrie: Das AMDP-System: Manual zur Dokumentation psychiatrischer Befunde. 3. korr. u. erw. Aufl. Springer, Berlin, Heidelberg, New YorkGoogle Scholar
  3. 3.
    Beckmann H, Haas St (1980). High dose diazepam in schizophrenia. Psychopharmacology 71: 79–82PubMedCrossRefGoogle Scholar
  4. 4.
    Crow TJ (1979). Biochemical effects of some new antidepressants: Putative mechanism of antidepressants effect. In: Dumont C (ed) Advances in pharmacology and therapeutics, Vol 5, Neuropsychopharmacology. Pergamon, OxfordGoogle Scholar
  5. 5.
    Feighner JP (1982). Benzodiazepines as antidepressants. In: Ban TA, Freyhan FA, Pöldinger W (eds) Modern Problems of Pharmacopsychiatry 18. Karger, Basel. 196–212Google Scholar
  6. 6.
    Guz I, Moraes R, Sartoretto IN (1972). The therapeutic effects of lorazepam in psychotic patients treated with haloperidol. Curr Ther Res 14: 767–774PubMedGoogle Scholar
  7. 7.
    Hamilton M (1976a) 048 HAMA. Hamilton Anxiety Scale. In: Guy W (ed) ECDEU Assessment Manual for Psychopharmacology. Rev Ed NIMH, Rockville, Maryland, pp 193–198Google Scholar
  8. 8.
    Hamilton M (1976b) 049 HAMD. Hamilton Depression Scale. In: Guy W (ed) ECDEU Assessment Manual for Psychopharmacology. Rev Ed NIMH, Rockville, Maryland, pp 179–192Google Scholar
  9. 9.
    Hanlon TE, Ota KY, Agallianos DD, Bergmann SA, Bethon GD, Kobler F, Kurland AA (1969). Combined drug treatment of newly hospitalized acutely ill psychiatric patients. Dis Nerv Syst 30: 104–116PubMedGoogle Scholar
  10. 10.
    Hanlon TE, Ota KY, Kurland AA (1970). Comparative effects of fluphenazine, fluphenazine-chlordiazepoxide, and fluphenazineimipramine. Dis Nerv Syst 31: 171–177PubMedGoogle Scholar
  11. 11.
    Hippius H (1972). The current status of treatment for depression. In: Kielholz P (ed) Depressive illness, diagnosis, assessment, treatment. Huber, Bern, pp 49–58Google Scholar
  12. 12.
    Janke W, Debus G (1977). Die Eigenschaftswörterliste (EWL) - Ein Verfahren zur Erfassung der Befindlichkeit. Hogrefe, Göttingen Toronto ZürichGoogle Scholar
  13. 13.
    Klein HE, Hippius H (1983). Angst-Diagnostik und Therapie in der täglichen Praxis. Adam Pharma Verlag GmbH, EssenGoogle Scholar
  14. 14.
    Kramer JC (1967). Treatment of chronic hallucinations with diazepam and phenothiazines. Dis Nerv Syst 28: 593–594PubMedGoogle Scholar
  15. 15.
    Laakmann G, Blaschke D, Hippius H and Messerer D (1986). Alprazolam versus amitriptyline in the treatment of depressed out-patients: a randomized double-blind trial. In: Lader MH, Davies HC (eds) Drug treatment of neurotic disorders: focus on alprazolam. Churchill Livingstone, Edinburgh London Melbourne and New YorkGoogle Scholar
  16. 16.
    Langer G, Heimann H (1983). Psychopharmaka: Grundlagen und Therapie. Springer, Wien New YorkGoogle Scholar
  17. 17.
    Lingjaerde O, Engstrand E, Ellingson P, Stylo DA, Robak OH (1979). Antipsychotic effect of Diazepam when given in addition to neuroleptics in chronic psychotic patients. Curr Ther Res 26: 505–514Google Scholar
  18. 18.
    Michaux MH, Kurland AA, Agallianos DD (1966). Chlorpromazine-chlordiazepoxide and chlorpromazine-imipramine treatment of newly hospitalized, acutely ill psychiatric patients. Curr Ther Res 8 (supp): 117–152PubMedGoogle Scholar
  19. 19.
    Nair NPV, Nestoros JN, Schwartz G (1981). High doses of diazepam improve neuroleptic-resistant schizophrenic patients. Abstract of the I II World Congress of Biological Psychiatry, StockholmGoogle Scholar
  20. 20.
    NIMH (1976) 028 CGI. Clinical Global Impressions. In: Guy W (ed) ECDEU Assessment Manual for Psychopharmacology. Rev Ed National Institute of Mental Health, Rockville, Maryland, pp 217–222Google Scholar
  21. 21.
    Rickels K, Case WG, Downing RW (1982). Issues in long-term treatment with diazepam therapy. Psychopharmacol Bull 18: 38–41Google Scholar
  22. 22.
    Rickels K, Feighner JP, Smith WT (1985). A double-blind comparison of alprazolam, amitriptyline, doxepin and placebo in the treatment of major depression. Arch Gen Psychiatry 42: 134–141PubMedCrossRefGoogle Scholar
  23. 23.
    Schatzberg AF, Cole JO (1978). Benzodiazepines in depressive disorders. Arch Gen Psychiatry 35: 1359–1365PubMedCrossRefGoogle Scholar
  24. 24.
    Zung WW (1976) 073 SDS. Self-Rating Depression Scale. In: Guy W (ed) ECDEU Assessment Manual for Psychopharmacology. Rev Ed NIMH, Rockville, Maryland, pp 333–336Google Scholar

Copyright information

© Dr. Dietrich Steinkopff Verlag, GmbH & Co. KG, Darmstadt 1987

Authors and Affiliations

  • G. Laakmann
  • D. Blaschke

There are no affiliations available

Personalised recommendations